News
ASND
137.20
-2.76%
-3.90
Ascendis Pharma Price Target Raised to $262.00/Share From $260.00 by Wells Fargo
Dow Jones · 1d ago
Ascendis Pharma Is Maintained at Overweight by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $262
Benzinga · 1d ago
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $170
Benzinga · 1d ago
Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target
Benzinga · 1d ago
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
Ascendantis Pharma reported results for the first quarter of 2024. The company reported earnings per share of -$2.50 and revenue of $104.15 million. Ascendis Pharma is a biopharmaceutical company that has been in the market for 20 years.
Investorplace · 2d ago
Ascendis Pharma A/S Boasts Strong Q1 Growth
TipRanks · 2d ago
Ascendis Pharma Posts Q1 Revenue Growth Amid Losses
TipRanks · 2d ago
Ascendis Pharma Outlines AGM Agenda and Proposals
TipRanks · 2d ago
Ascendis Pharma reports Q1 results
Ascendis Pharma reports Q1 results May 02, 2024. Q1 GAAP EPS of -€2.30. Revenue of €95.9M. Full year 2024 SKYTROFA revenue expected to be €320 million to €340 million. Expect to be operating cash flow breakeven by the end of 2024.
Seeking Alpha · 2d ago
Biotech Stocks Facing FDA Decision In May 2024
NASDAQ · 4d ago
Weekly Report: what happened at ASND last week (0422-0426)?
Weekly Report · 6d ago
Looking Into Ascendis Pharma's Recent Short Interest
Ascendis Pharma's short percent of float has risen 13.75% since its last report. The company has 3.35 million shares sold short. Short interest is the number of shares that have been sold short but have not yet been covered. Short selling is when a trader sells shares with the hope that the price will fall.
Benzinga · 04/26 15:30
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Ascendis Pharma A/S will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024. The company will also host a conference call and live webcast to discuss its financial results. Ascendis Pharma will report its results after the close of the U.S. Financial markets.
Barchart · 04/25 15:46
Ascendis Pharma Gains UK Authorization for YORVIPATH
TipRanks · 04/24 13:57
Ascendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidism
NASDAQ · 04/24 13:21
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
NASDAQ · 04/24 12:34
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).